pancreatic cancer
Oncology · 2014–2019
3decisions
3medicines
1carried consumer input
2individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| paclitaxel, nanoparticle albumin-bound A 250 mg strength of nanoparticle albumin-bound paclitaxel for Stage IV (metastatic) adenocarcinoma of the pancreas in combination with gemcitabine, metastatic… | Mar 2019 | Recommended | none received |
| irinotecan (nanoliposomal) Treatment of metastatic pancreatic adenocarcinoma in adult patients with disease progression who have previously received gemcitabine-based therapy, in… | Nov 2016 | Not recommended | 2 individuals Medical Oncology Group · Pancare Foundation · Rare Cancers Australia |
| paclitaxel-nanoparticle albumin bound First-line treatment of locally advanced, unresectable or metastatic adenocarcinoma of the pancreas in combination with gemcitabine. | Mar 2014 | Recommended with restriction | unclear |
Who spoke
Medical Oncology Group · Pancare Foundation · Rare Cancers Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.